The Effects of Anti-angiogenesis on Enoxaparin Cutaneous Emulsion on Induced Breast Cancer in Female Rats

Publish Year: 1396
نوع سند: مقاله کنفرانسی
زبان: English
View: 380

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

IPMCMED02_158

تاریخ نمایه سازی: 29 فروردین 1397

Abstract:

Introduction: Studies have shown that there is a significant relationship between Heparin and female cancer. The present study examines the anti-angiogenesis effect of the enoxaparin skin lotion on breast cancer induced by dimethyl benzene anthracene.Methods: In this experimental laboratory study, 50 female rats were divided into intact, control and animals treated with enoxaparin (40, 60 and 80 mg %). After one month after, breast tissue samples were provided and stained using hematoxylin-eosin staining method and tumor suppression rate was calculated. The data were analyzed using one-way analysis of variance (ANOVA).Results: The percentage of tumor suppression significantly increased in groups treated with enoxaparin compared to control group (P<0.01), and also tumor suppression rate significantly increased in dose-dependent pattern with increasing of enoxaparin dose (P<0.01). Conclusion: The results of this study demonstrate that enoxaparin has an inhibitory effect on the breast tumor size in a dose-dependent way; according to which, applying of enoxaparin in patients with breast cancer may have considerable role in considered in inhibition of tumor growth.

Authors

M Bolandpayeh

Department of Pharmacology& Toxicology, Faculty of Pharmacy, Pharmaceutical Branch ,Islamic Azad University, Tehran, Iran.(IAUPS)

M Hassanpour Ezzati

Department of Physiology, Faculty of Sciences School, Shahed University, Tehran, Iran

Z Mousavi

Department of Pharmacology& Toxicology, Faculty of Pharmacy, Pharmaceutical Branch, Islamic Azad University, Tehran, Iran.(IAUPS)